It takes some digging but if you look under Fidelity's Company Research Highlights, it also says 22.6%.

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of
treatments for multiple therapeutic indications.
Key Statistics
Employee Count 9
Institutional Ownership 22.6%
Total Revenue (TTM) $0.00